Ignite Creation Date:
2024-05-06 @ 3:03 PM
Last Modification Date:
2024-10-26 @ 1:42 PM
Study NCT ID:
NCT04507230
Status:
COMPLETED
Last Update Posted:
2021-03-11
First Post:
2020-08-07
Brief Title:
COVID-19 Associated Coagulopathy in Egypt
Sponsor:
Assiut University
Organization:
Assiut University
Study Overview
Official Title:
Assessment of COVID-19 Associated Coagulopathy and Hypercoagulable State in Upper Egypt
Status:
COMPLETED
Status Verified Date:
2021-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Coagulopathy is one of the most significant prognostic factors in patients with COVID-19 and is associated with increased mortality and admission to critical care Most commonly observed coagulopathy in patients hospitalized with COVID-19 COVID-19-associated coagulopathy is characterized by increased D-dimer and fibrinogen levels 71 of patients who did not survive hospitalization reported to have developed disseminated intravascular coagulation DIC compared to 06 of survivors
Detailed Description:
studying the detailed coagulation screen and second line coagulation parameters including both thrombophilia screen and other acute phase coagulation factors
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None